Last edition
News about "Retatrutide "
Lilly Urges Action against Illegal Retatrutide Black Market
Eli Lilly has filed 6 new lawsuits against US entities selling illegal retatrutide products, escalating efforts to protect patients from the black market.
Retatrutide | 12/08/2026 | By News Bureau
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials. The company plans to submit a Biologics License Application (BLA) for retatrutide to the US Food and Drug Administration (FDA) in Q1 2027.
Retatrutide | 25/07/2026 | By News Bureau | 116
Lilly's Retatrutide Shows Strong A1C, Weight Reduction in Phase-III Diabetes Trial
Eli Lilly’s Retatrutide reduced A1C by up to two percent and delivered average weight loss of 36.6 lbs in its phase-III TRANSCEND-T2D-1 trial, with continued weight reduction observed through 40 weeks in type-II diabetes mellitus patients.
Retatrutide | 20/03/2026 | By News Bureau | 182
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy